BiotechTV explores the BioEscalator's role in nurturing start-ups
30 April 2024
Brad Loncar visited the BioEscalator to learn more about how we support the growth of innovative medical science companies.
Integrated cancer biotech Infinitopes secures £12.8M seed financing to enhance its Precision Immunomics(TM) antigen discovery technologies to target five more cancers
30 April 2024
Funding also supports the start of phase I/IIa study for lead vaccine, ITOP1
MediMabBio signs MOU with PDC*line Pharma to collaborate on cancer immunotherapy
30 April 2024
MediMabBio has announced a new memorandum of understanding (MOU) with PDCline Pharma. This collaboration aims to explore the synergy between MediMabBio's MMB101/MFA011 and PDC*line Pharma’s plasmacytoid dendritic cell (PDC) cancer vaccines to revolutionise cancer treatment. Together, their promising drug candidates, targeting TIGIT and other immuno-oncology pathways, would enhance the efficacy of PDC cancer vaccines. By leveraging PDC*line Pharma’s expertise, MediMabBio aims to boost the efficacy of its therapies and explore innovative treatment strategies.
CardiaTec joins the BioEscalator - AI in cardiovascular drug discovery
17 April 2024
The BioEscalator welcomes CardiaTec, a spin-out company from the University of Cambridge that employs computational methods to decode the biology behind cardiovascular disease.
MediMabBio - Two time zones, one mission
10 April 2024
Two clocks are visible behind the Chief Scientific Officer of MediMabBio, Dr Chris Willberg, as he sits in the company office at the BioEscalator – showing time zones seven hours apart, they are a reminder of how teams in Seoul and Oxford are working together to discover new treatments for cancer and autoimmune disease.
Exogene announces strategic collaboration with Immunocore to engineer T-Cell receptors using artificial intelligence
3 April 2024
Exogene is excited to announce a research collaboration with TCR therapy industry leader Immunocore, developer of a novel class of TCR-based bispecific treatments for oncology, infectious diseases and autoimmune diseases using their proprietary ImmTAX technology. The purpose of the collaboration is to accelerate the discovery of high-affinity TCRs, with a vision to ultimately accelerate the development of TCR-based bispecific therapies across multiple targets and indications.
Granza Bio: Pioneering personalised and targeted cancer therapeutics
3 April 2024
The BioEscalator is pleased to welcome Granza Bio, a biotech startup founded by two PhD graduates in oncology and immunology from the University of Oxford. Granza Bio is pioneering a new era in cancer therapeutics by developing personalised and targeted cancer treatments using the body's own immune system.
It started with a brainstorm
20 March 2024
Companies start in all kinds of different ways, and for Bioarchitech it was brainstorming that generated the idea behind the enterprise. It is now planning a Series A fundraising to bring its lead candidate to the clinic. Bioarchitech is focused on cancer, developing oncolytic viruses encoding protein immunotherapies for the destruction of tumours, ideally with just one or two doses.
Infinitopes has a double victory at the 15th Annual OBN Awards 2023
23 November 2023
The OBN Awards recognise companies that demonstrate outstanding leadership, innovative practices, and significant contributions towards addressing clinical needs at different stages of development.
Celebrating 5 years of the Oxford BioEscalator
15 October 2023
The BioEscalator recently marked its 5th anniversary with a celebration that showcased the impressive journeys of some of its current and graduated biotech companies.
Hutano Diagnostics acquired by EDX Medical Group
28 September 2023
We are delighted that BioEscalator resident start-up Hutano Diagnostics has announced its acquisition by Cambridge, UK-based EDX Medical Group PLC.
Oxford Silk Phage Technologies secures top spot in BioCap 2023 pitch competition
28 September 2023
Despite facing tough competition, Oxford Silk Phage Technologies impressed the judges with its presentation, earning the top spot in the competition.
Inspiring stories shared at The Africa Oxford Health Innovation platform programme
30 August 2023
The BioEscalator community engaged with the talented cohort of innovators from The Africa Oxford Health Innovation Platform (AfOx-HIP) programme, a collaborative initiative by the University of Oxford fostering innovation and entrepreneurship to address crucial health challenges in Africa.
Infinitopes announced as OBN Awards 2023 finalist in two categories
17 August 2023
We are pleased to announce that Infinitopes has been named as a finalist in two categories for the upcoming OBN Awards 2023. The company's consistent excellence earned it recognition in the Best Start-up Biotech category for the second year while being selected as a finalist for the esteemed BioSeed 'One to Watch' category.
BioEscalator Pitch Battle 2023
12 July 2023
Pitching a business idea to potential investors is nerve-wracking for any entrepreneur. The pressure to effectively convey a company's vision, potential, and market viability can be overwhelming. However, for the innovative companies associated with the BioEscalator, this task became an opportunity to shine at the fourth annual BioEscalator Pitch Battle.
BioEscalator presented with LEAF Bronze Award at the Vice Chancellor’s Environmental Sustainability Awards 2023
19 June 2023
The BioEscalator, alongside resident company Alethiomics, was presented with the award, showing commitment towards sustainable practices.